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IntroductIon L‑asparaginase is an enzyme 
of the hydrolase class that catalyzes the degra‑
dation of L‑asparagine – an amino acid (amide 
of 2‑aminosuccinic acid), to aspartic acid and am‑
monia. This enzyme is present in numerous bacte‑
ria, plants and animals. However, it has not been 
found in humans. The presence of L‑asparagine 
is essential for a normal course of the cell cycle. 
In most human cells the deficit of the endogenous 
asparagine may be compensated by alternative 
synthesis from aspartic and glutamine acid in‑
volving the asparagine synthase. This enzyme is 
absent in certain neoplasmatic cells, particular‑
ly in lymphoblasts, thus the depletion of L‑as‑
paragine from the plasma leads to DNA, RNA 
and protein synthesis inhibition and in conse‑
quence to blast cell apoptosis. L‑asparaginase 
demonstrates relative substrate specificity and 
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L‑asparaginase is a hydrolase that catalyzes the conversion of L‑asparagine – an endogenous amino 
acid necessary for the function of some neoplastic cells, such as lymphoblasts. In most human cells 
deficiency of L‑asparagine can be compensated by alternative synthesis pathway through which 
L‑asparagine is produced from aspartic acid and glutamine by asparagine synthethase. Depletion 
of L‑asparagine from plasma by L‑asparaginase results in inhibition of RNA and DNA synthesis with 
the subsequent blastic cell apoptosis. Owing to the unique anti‑cancer mechanism of action, L‑as‑
paraginase has been introduced to the multi drug chemotherapy in children and adults with acute 
lymphoblastic leukemia, which has contributed to significant improvement of therapy outcomes 
and to achieve complete remission in about 90% of patients. Notwithstanding its high therapeutic 
efficacy, L‑asparaginase can increase the risk of thrombosis. Inhibition of protein synthesis causes 
most complications observed during treatment with a native and pegylated form of L‑asparaginase, 
including impaired functions of liver, kidneys or central nervous system. Thrombotic events occur as 
a result of inhibited synthesis of anticoagulant proteins (mainly antithrombin). Coagulopathy has been 
observed in 1.1–4% of patients treated with the pegylated L‑asparaginase and in 2.1–15% of those 
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of plasma asparagine elimination in compari‑
son with native L‑asparaginase. The influence 
of the type of L‑asparaginase preparation used, 
and the magnitide of decrease in asparagine plas‑
ma levels on treatment outcomes were not as‑
sessed in any of these studies.
In the recently published study, Cancer and Leu‑
kemia Group B (CALGB) with the use of PEG‑ASP 
in induction treatment and early intensification 
in ALL adult patients the influence of asparag‑
ine elimination on a significantly longer over‑
all survival (OS) and disease free survival (DFS) 
has been reported for the first time. In patients 
in whom as a result of pegylated asparaginase 
administration an efficacious plasma elimina‑
tion was achieved, and not achieved (defined as 
the plasma asparaginase level over 0.03 U/ml last‑
ing for 14 days after administration of minimum 
1 of the 4 doses of 2000 U/m2 of PEG‑ASP), OS 
and DFS were 31 and 25 months, and 13 and 12 
months, respectively.6
thrombotic complications Treatment of ALL 
with L‑asparaginase may lead to a severe ac‑
quired deficiency of serpin class of proteins (in‑
hibitors of serine proteases), mainly antithrom‑
bin (AT) and αα1‑antitrypsin. Studies showed that 
the prevalence of these complications in children 
and adults receiving the native drug preparation 
and the pegylated form is 2.1–15% and 1.1–4%, 
respectively.15,16
Antithrombin is the main physio logic inhibitor 
of thrombin and coagulant factors IXa, Xa, XIa. 
It also antagonizes the activity of factor VII ac‑
celerating the dissociation of complexes formed 
by factor VIIa and tissue factor. Antithrombin 
forms irreversible links with active enzymes 
which deprives them of their proteolytic prop‑
erties. The prevalence of AT deficiency in the pop‑
ulation is estimated at 0.02–0.05%. The congeni‑
tal or acquired AT deficiency is reported in about 
2% of thrombotic patients. Genetic studies have 
demonstrated a high heterogeneity of the congen‑
ital AT deficiency, and on the basis of these stud‑
ies type I quantitative and type II deficiency (with 
3 subtypes of protein qualitative defect) have 
been distinguished. In type I deficiency (as a re‑
sult of deletion or point mutation in antithrom‑
bin gene that determines AT synthesis) a normal 
protein synthesis decrease (a reduction in its ac‑
tivity), and the AT antigen level decrease are not‑
ed. Qualitative type II is characterized by a defect 
within the reactive site of the molecule (usually 
the substitution of a single amino acid) responsi‑
ble for a decrease in AT inhibitor activity, or a de‑
fect of the heparin binding region (so called HBS – 
heparin binding site mutation). In qualitative de‑
ficiency subtype III there are multiple abnormal‑
ities in the reactive site, the heparin binding site 
and a decreased AT plasma level. All type I and II 
deficiencies are inherited in an auto somal domi‑
nant manner, with the exception of the heparin 
binding region defect, inherited as an auto somal 
recessive trait.
at the same time affects the glutamine meta‑
bolism, which may intensify adverse effects in‑
cluding hepatotoxicity, hemo static disorders and 
hyperglycemia.1 Antitumor features of L‑aspar‑
aginase have been first studied in 1953 by Kidd 
who observed lymphoma regression in mice and 
rats in response to the guinea pig plasma.2 Fur‑
ther studies have demonstrated that L‑asparagi‑
nase enzyme accounts for this effect; the mech‑
anism of action of this enzyme has been eluci‑
dated.3 In the early 70s L‑asparaginase was in‑
troduced to combined chemotherapy protocols, 
mainly in acute lymphoblastic leukemia (ALL) 
and in non‑Hodgkin lymphoma in children, which 
significantly improved treatment outcomes (93% 
remission after induction).4
Properties and efficacy L‑asparaginase is an im‑
portant component of induction and consolida‑
tion multidrug chemotherapy in children and 
adults with ALL. The natural (native) forms 
of the enzyme, produced by Erwinia chrysanthe-
mi and Escherichia coli bacteria strains are used 
in treatment, and the E. coli L‑asparaginase de‑
rivative, covalently bound with mono methoxy 
polyethylene glycol (Peg‑asparaginase, PEG‑ASP) 
of prolonged half‑life. The plasma L‑asparagi‑
nase half‑time for the pegylated form is 5.5 
days, whereas for the native form it is 26 hours.5 
Chemotherapy protocols for ALL recommend 
the dose of 1000–2500 IU/m2 of PEG‑ASP, and 
for the native form 5000–12,000 IU/m2.6 There 
has been published so far one randomized study 
comparing the properties and clinical efficacy 
of E. coli native and pegylated L‑asparaginase 
in children with newly diagnosed ALL. It demon‑
strated a more rapid bone marrow blast cell elimi‑
nation (studied on the 7th and 14th day of induc‑
tion), L‑asparaginase plasma activity time prolon‑
gation, and a lower drug immunogenicity in sub‑
jects treated with the pegylated form.
In the case of repeated use of the same drug 
in consolidation, a high titer of anti‑L ‑ asparagi‑
nase antibodies has been reported in 26% of pa‑
tients treated with the native drug and in 2% 
of those treated with the pegylated form. The use 
of PEG‑ASP results in maintaining a constant 
high plasma level of this enzyme with a low titer 
of antibodies neutralizing its activity with each 
use. No significant differences were reported re‑
garding toxic symptoms and the risk of infectious 
complications or the percentage of achieved to‑
tal complete remissions in both arms.5 In earli‑
er published studies on adult patients and chil‑
dren the presence of E.coli L‑asparaginase anti‑
bodies during multiple administrations was re‑
ported in 28–96% of patients, while severe al‑
lergic reactions were observed in 24% of children 
and 29% of adults.7
The efficacy of pegylated asparaginase was 
assessed in studies on children with recurrent 
ALL,8‑10 in induction treatment,5,11and in induc‑
tion in ALL adults.12‑14 These studies demonstrat‑
ed a good drug tolerance and a greater efficacy 
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(a dose of 6000 IU/m2 s.c. for 7 days).19,20 Dur‑
ing AT prophylactic administration, coagulopathy 
syndromes, and proteins C and S, plasminogen, 
αα2‑antiplasmin, factor VII and platelet count al‑
terations were not observed.20
Subsequent studies have confirmed the efficacy 
of such management during L‑asparaginase treat‑
ment in adults: thrombotic complications occur‑
red only in patients not receiving AT prophylaxis 
(27% vs. 0% in the prophylaxis group).21
The only randomized controlled trial published 
so far, PARKAA (Prophylactic Antithrombin Re‑
placement in Kids with Acute Lymphoblastic 
Leukemia Treated with Asparaginase), that as‑
sessed the safety and efficacy of AT prophylactic 
administration in children treated with L‑aspara‑
ginase, demonstrated a tendency towards a small‑
er percentage of thrombi in the group treated 
with AT (28%) in comparison with the group 
not receiving AT (37%). To diagnose thrombo‑
sis, phlebography, vein ultrasound, echocardiog‑
raphy and magnetic resonance examinations have 
been performed.22,24
The most recent reports published by pediatric 
groups indicate the role of combined prophylaxis 
with low‑molecular‑weight heparin (enoxaparin 
AT at the dose of 1 mg/kg/day) and AT in throm‑
botic complications prophylaxis in children (lack 
of thrombotic complications in the group re‑
ceiving combined prophylaxis with enoxaparin 
and AT vs. 12.7% in the group receiving AT as 
prophylaxis).23
The analysis of congenital and acquired hemo‑
stasis disorders which may increase the risk 
of thrombotic events in children treated with 
L‑asparaginase demonstrated a prothrombotic 
tendency in those with antiphospholipid anti‑
bodies.23 This suggests the purposefulness of ex‑
cluding the antiphospholipid syndrome, deficien‑
cy of congenital and acquired coagulation inhibi‑
tors and resistance to activated C protein, before 
introducing asparaginase treatment in patients 
with a history of thrombosis.
In case of suspected inherited thrombophil‑
ia, indications for this therapy should be consid‑
ered on the individual basis. Patients who after 
administration of PEG‑ASP had thrombotic or 
hemo rrhagic complications should not receive 
native L‑asparaginase.
Adverse effects related to protein synthesis inhibi-
tion The majority of adverse effects during L‑as‑
paraginase treatment are related with a transient 
protein inhibition in the liver and pancreas. In‑
creased activity of hepatic enzymes, including 
aminotransferases, alkaline phosphatase, and 
increased serum billirubin levels occur in 5–16% 
of patients with PEG‑ASP administration (for 14 
days) and in nearly 100% patients after native 
L‑asparaginase treatment. Acute pancreatitis is 
one of the most severe complications common‑
ly occurring without a significant increase in, or 
with normal enzyme levels, pancreatic amylase 
and lipase (the effect of their synthesis inhibition 
Acquired antithrombin deficiency may result 
from defective synthesis (liver diseases, protein 
losing enteropathy), an increased consumption 
during acute thrombosis, intravascular coagula‑
tion syndrome with fibrinolysis activation, sep‑
sis, hemo lytic post‑transfusion reaction, neph‑
rotic syndrome (protein loss) and as the result 
of heparin, L‑asparaginase, and oral contracep‑
tives and estrogen treatment (a negligible lev‑
el decrease).
The influence of L‑asparaginase on the level, 
activity and conformation of plasma AT mole‑
cules in ALL patients was assessed, and ultra‑
structure alterations were studied in mouse he‑
patic cells arising from L‑asparaginase intraperi‑
toneal injections, and in vitro in HepG2 cell lines 
(human hepatoma) incubated with L‑asparagi‑
nase. It has been reported that with L‑asparagi‑
nase there is an antithrombin molecule confor‑
mation change and stability loss, and as a conse‑
quence, formation of protein aggregates which ac‑
cumulate in the endoplasmatic reticulum cisterns. 
In effect there is antithrombin secretion impair‑
ment as in its genetically determined type I de‑
ficiency. Conformation alterations, as in the case 
of other serpins (serine proteases inhibiting pro‑
teins) induce a loss of plasticity of AT molecules 
which determines its proper function. L‑aspara‑
ginase alters conformation and enhances intracel‑
lular accumulation of formed AT molecules. They 
are regarded as the main mechanism responsible 
for thrombotic complications in patients treated 
with L‑asparaginase preparations.17
It has also been demonstrated that despite 
a significantly decreased fibrinogen level there 
may be L‑asparaginase treatment induced throm‑
bosis, which results mainly from the synthesis in‑
hibition, not from consumption in the process 
of thrombosis. In the group of 93 ALL patients 
analyzed, there were 9 in 93 (10%) thrombotic ep‑
isodes including 6 in 93 (7%) with L‑asparaginase 
treatment. A decrease in plasma fibrinogen levels 
below 50 mg/dl reported in 12 in 93 cases (13%) 
significantly correlated with the risk of thrombot‑
ic events. Several investigators showed that a sig‑
nificant reduction in fibrinogen levels (<50 mg/dl) 
in L‑asparaginase‑treated patients reflects the de‑
gree of protein synthesis inhibition, including AT, 
which leads to the conclusion that measurements 
of fibrinogen levels may serve as a useful and eas‑
ily accessible indicator of the risk of thrombosis 
occurrence in this group of patients.18
Some authors recommend antithrombin sub‑
stitution when its plasma level decreases below 
60% of normal values during L‑asparaginase 
treatment, aiming at decreasing the thrombot‑
ic risk.
In the studies GIMEMA (Gruppo Italiano 
Malattie Emato logiche Maligne dell’Adulto) 
by an Italian group including adult patients, 
the following AT dosage scheme is recommended 
for prophylaxis: 20–25 and 50 IU/kg of body mass 
for 7–10 consecutive days, beginning on the day 
of the native L‑asparaginase treatment start 
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AT prophylaxis time is about 10 days, for PEG‑ASP 
(a single dose, activity time about 5.5 days), 
the period of administration is estimated indi‑
vidually with hemo static and AT system mon‑
itoring. If AT preparations cannot be adminis‑
tered, fresh frozen plasma preparations may be 
used as a substitute.
3 Patients with thromboembolic disease should 
not receive L‑asparaginase treatment.
4 L‑asparaginase administration requires coag‑
ulation system and bio chemical para meter moni‑
toring including hepatic enzymes, pancreatic am‑
ylase, glycemia, and acid‑base balance.
rEfErEncEs
1 Müller HJ, Boos J. Use of L‑asparaginase in childhood ALL. Crit Rev On‑
col Hematol. 1998; 28: 97‑113.
2 Kidd JG. Regression of transplanted lymphomas induced in vivo 
by means of normal guinea pig serum. I. Course of transplanted cancers 
of various kinds in mice and rats given guinea pig serum, horse serum, or 
rabbit serum. J Exp Med. 1953; 98: 565‑582.
3 Broome JD. L‑Asparaginase: discovery and development as a tumor‑in‑
hibitory agent. Cancer Treat Rep. 1981; 65: 111‑114.
4 Ortega JA, Nesbit ME Jr, Donaldson MH. L‑Asparaginase, vincristine, 
and prednisone for induction of first remission in acute lymphocytic leuke‑
mia. Cancer Res. 1977; 37: 535‑540.
5 Avramis VI, Sencer S, Periclou AP, et al. A randomized comparison 
of native Escherichia coli asparaginase and polyethylene glycol conju‑
gated asparaginase for treatment of children with newly diagnosed stan‑
dard‑risk acute lymphoblastic leukemia: a Children’s Cancer Group study. 
Blood. 2002; 99: 1986‑1994.
6 Wetzler M, Sanford BL, Kurtzberg J, et al. Effective asparagine deple‑
tion with pegylated asparaginase results in improved outcomes in adult 
acute lymphoblastic leukemia: Cancer and Leukemia Group B Study 9511. 
Blood. 2007; 109: 4164‑4167.
7 Woo MH, Hak LJ, Storm MC, et al. Hypersensitivity or development 
of antibodies to asparaginase does not impact treatment outcome of child‑
hood acute lymphoblastic leukemia. J Clin Oncol. 2000; 18: 1525‑1532.
8 Ettinger LJ, Kurtzberg J, Voute PA, et al. An open‑label, multicenter 
study of polyethylene glycol‑L ‑ asparaginase for the treatment of acute 
lymphoblastic leukemia. Cancer. 1995; 75: 1176‑1181.
9 Müller HJ, Löning L, Horn A, et al. Pegylated asparaginase (On‑
caspar) in children with ALL: drug monitoring in reinduction according 
to the ALL/NHL‑BFM 95 protocols. Br J Haematol. 2000; 110: 379‑384.
10 Jarrar M, Gaynon PS, Periclou AP, et al. Asparagine depletion after pe‑
gylated E. coli asparaginase treatment and induction outcome in children 
with acute lymphoblastic leukemia in first bone marrow relapse: A Chil‑
dren’s Oncology Group study (CCG‑1941). Pediatr Blood Cancer. 2006; 47: 
141‑146.
11 Rizzari C, Citterio M, Zucchetti M, et al. A pharmaco logical study 
on pegylated asparaginase used in front‑line treatment of children with 
acute lymphoblastic leukemia. Haemato logica. 2006; 91: 24‑31.
12 Rosen O, Muller HJ, Gokbuget N, et al. Pegylated asparaginase in com‑
bination with high‑dose methotrexate for consolidation in adult acute lym‑
phoblastic leukaemia in first remission: a pilot study. Br J Haematol. 2003; 
123: 836‑841.
13 Douer D, Yampolsky H, Cohen LJ, et al. Pharmacodynamics and safe‑
ty of intravenous pegaspargase during remission induction in adults aged 
55 years or younger with newly diagnosed acute lymphoblastic leukemia. 
Blood. 2007; 109: 2744‑2750.
14 Hołowiecki J, Giebel S, Krawczyk M, et al. PEG‑Asparaginase as a Part 
of Induction Therapy for Adult Acute Lymphoblastic Leukemia. A Phase II 
Study by the Polish Adult Leukemia Group (PALG). 45‑th Annual Meeting 
of ASH, 6–9.12.2003 San Diego, USA. Blood. 2003; 102: 255b.
15 Nowak‑Göttl U, Ahlke E, Fleischhack G, et al. Thromboembolic events 
in children with acute lymphoblastic leukemia (BFM protocols): prednisone 
versus dexamethasone administration. Blood. 2003; 101: 2529‑2533.
16 Holle LM. Pegaspargase: an alternative? Ann Pharmacother. 1997; 31: 
616‑623.
17 Hernandez‑Espinoza D, Minano A, Martinez C, et al. L‑Asparaginase‑in‑
duced antithrombin type I deficiency. Am J Pathol. 2006; 169: 142‑153.
18 Beinart G, Damon L. Thrombosis associated with L‑asparaginase ther‑
apy and low fibrinogen levels in adult acute lymphoblastic leukemia. Am J 
Hematol. 2004; 77: 331‑335.
19 Mattioli Belmonte M, Gugliotta L, Delvos U, et al. A regimen for anti‑
thrombin III substitution in patients with acute lymphoblastic leukemia un‑
der treatment with L‑asparaginase. Haemato logica. 1991; 76: 209‑214.
by L‑asparaginase). It occurs in 1–5.7% of patients 
treated with the pegylated form and in about 10% 
of patients receiving the native form. Concomi‑
tant clinical symptoms are not characteristic (nau‑
sea, vomiting, and abdominal pain). In the major‑
ity of cases the inflammation is subclinical and 
resolves with the drug activity cessation. Total 
parenteral nutrition and decompression stom‑
ach tube insertion are recommended in manage‑
ment. L‑asparaginase induced pancreatitis in sin‑
gle cases may have a fulminant hemo rrhagic or 
necrotic course and has a fatal prognosis.16 Sin‑
gle case reports, mainly in children, document‑
ed an efficacious therapy with the use of percu‑
taneous drainage and pancreas site rinsing in ne‑
crotic pancreatitis.25 Patients with previous acute 
pancreatitis cannot be treated with L‑asparagi‑
nase preparations.
Insulin synthesis inhibition, glutamine meta‑
bolism disorders and simultaneous use of corti‑
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with the use of the native form in about 4% of pa‑
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summArY 1 It is considered that the immu‑
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ment can be reduced by prophylaxis with AT prep‑
arations at the dose of 25–50 IU/kg from the day 
of treatment initiation through the whole period 
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